Balyasny Asset Management LLC bought a new stake in shares of Radius Health, Inc. (NASDAQ:RDUS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 73,374 shares of the biopharmaceutical company’s stock, valued at approximately $3,319,000. Balyasny Asset Management LLC owned about 0.17% of Radius Health at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. BB Biotech AG grew its holdings in shares of Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after purchasing an additional 135,071 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after purchasing an additional 262,896 shares during the last quarter. Pictet Asset Management Ltd. grew its holdings in shares of Radius Health by 20.0% during the second quarter. Pictet Asset Management Ltd. now owns 641,388 shares of the biopharmaceutical company’s stock valued at $22,205,000 after purchasing an additional 106,849 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in shares of Radius Health during the second quarter valued at approximately $25,589,000.
In related news, major shareholder Growth N. V. Biotech purchased 60,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average price of $35.98 per share, with a total value of $2,158,800.00. Following the completion of the acquisition, the insider now directly owns 5,248,799 shares in the company, valued at approximately $188,851,788.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 150,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now owns 5,113,799 shares of the company’s stock, valued at $178,829,551.03. The disclosure for this purchase can be found here. In the last three months, insiders purchased 469,100 shares of company stock valued at $16,328,382. 15.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/10/11/balyasny-asset-management-llc-invests-3-32-million-in-radius-health-inc-rdus.html.
Shares of Radius Health, Inc. (RDUS) opened at 37.21 on Wednesday. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $55.97. The firm has a 50-day moving average price of $36.69 and a 200-day moving average price of $38.73. The firm’s market capitalization is $1.62 billion.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.23). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same period in the prior year, the company posted ($1.01) earnings per share. On average, equities research analysts anticipate that Radius Health, Inc. will post ($5.55) EPS for the current year.
Several research firms have recently commented on RDUS. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $38.00 price objective (up from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $52.17.
Radius Health Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.